Wall Street Transcript Interview with Peter R. Culpepper, the CFO and COO of Provectus Pharmaceuticals, Inc. (PVCT)
67 WALL STREET, New York - September 19, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Health Care - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends
Companies include: Provectus Pharmaceuticals, Inc. (PVCT) and many more.
In the following excerpt from the Biotechnology and Pharmaceuticals Report, the CFO and COO of Provectus Pharmaceuticals, Inc. (PVCT) discusses company strategy and the outlook for this vital industry:
TWST: Give us your thoughts on the market potential for PV-10.
Mr. Culpepper: We're looking at very large unmet needs in numerous indications, so we're looking at truly a multibillion-dollar opportunity from a revenue standpoint.These are large markets, and not just melanoma; primary liver cancer, globally, is a very challenging indication. We have clinical success with PV-10 in treating primary liver cancer and breast cancer as well. We've also expanded into other indications through our compassionate use program, under which the FDA is letting us use our drug for people who have no other treatment options. So among all these different indications we have a basis to go into human studies because of the preclinical data.
We believe we could potentially do something along the lines of a Celgene-Abraxis type transaction, where Celgene acquired Abraxis for $2.9 billion upfront, plus shareholders got a contingency value right for the shares that they owned in Abraxis, so that's a tradable security. Sanofi did the same thing with Genzyme. So we would look at - and we have disclosed this in our SEC filings - an appropriate acquisition, primarily because we are a development company.
We don't plan to commercialize PV-10, like, for example, Celgene did around thalidomide. We are planning to partner up, which we disclosed in the SEC filings, and then eventually be acquired. But we want significant upside for our shareholders, and we believe the potential of our compound in multiple indications does warrant a significant upfront as well as the contingency value.
Our business valuation analysis has determined that...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
